Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.08 is 91% above its 3-year average of 0.04, around the middle of its 3-year range (-0.10–0.19).
As of the fiscal period ended Tuesday, June 30, 2026. 9.30% below its 12-month average of 0.09.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.08.
DEBT TO EQUITY RATIO
0.08
DEBT TO EQUITY RATIO AVG TTM
0.09
DEBT TO EQUITY RATIO AVG 3Y
0.05
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-9.30%
CURRENT VS 3Y AVG
+77.58%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.16
median of 351 covered companies
CURRENT VS SECTOR MEDIAN
-49.65%
vs the sector median at left
Market Cap
$852.55M
Debt to Equity Ratio
0.03
TTM Avg
0.07
3Y Avg
0.07
5Y Avg
0.07
Market Cap
$867.60M
Debt to Equity Ratio
0.08
TTM Avg
0.18
3Y Avg
0.20
5Y Avg
0.16
Market Cap
$786.48M
Debt to Equity Ratio
0.08
TTM Avg
0.06
3Y Avg
0.05
5Y Avg
0.04
Market Cap
$903.13M
Debt to Equity Ratio
0.00
TTM Avg
0.03
3Y Avg
0.03
5Y Avg
0.03
Market Cap
$780.95M
Debt to Equity Ratio
1.50
TTM Avg
1.31
3Y Avg
1.32
5Y Avg
1.45
Market Cap
$776.24M
Debt to Equity Ratio
0.56
TTM Avg
0.77
3Y Avg
0.65
5Y Avg
0.53
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alumis Inc. (ALMS) | $844.28M | 0.08 | 0.09 | 0.05 | N/A |
| Ardelyx, Inc. (ARDX)vs › | $837.43M | 1.72 | 1.08 | 0.72 | 0.64 |
| Beta Bionics, Inc. (BBNX)vs › | $852.55M | 0.03 | 0.07 | 0.07 | 0.07 |
| Apnimed, Inc. (APMD)vs › | $866.15M | N/A | N/A | N/A | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $867.60M | 0.08 | 0.18 | 0.20 | 0.16 |
| Cytek Biosciences, Inc. (CTKB)vs › | $786.48M | 0.08 | 0.06 | 0.05 | 0.04 |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $903.13M | 0.00 | 0.03 | 0.03 | 0.03 |
| AdaptHealth Corp. (AHCO)vs › | $780.95M | 1.50 | 1.31 | 1.32 | 1.45 |
| Geron Corporation (GERN)vs › | $776.24M | 0.56 | 0.77 | 0.65 | 0.53 |
| Design Therapeutics, Inc. (DSGN)vs › | $775.72M | 0.01 | 0.01 | 0.01 | 0.01 |
Debt/Equity
0.08
Current Ratio
6.74
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.08 |
| 2026-03-31 | 0.06 |
| 2025-12-31 | 0.12 |
| 2025-09-30 | 0.10 |
| 2025-06-30 | 0.08 |
| 2025-03-31 | 0.19 |
| 2024-12-31 | 0.12 |
| 2024-09-30 | 0.09 |
| 2024-06-30 | -0.07 |
| 2024-03-31 | -0.08 |
| 2023-12-31 | -0.10 |
| 2023-09-30 | 0.00 |
| 2023-06-30 | 0.00 |
| 2023-03-31 | 0.00 |
